Some people may know of this drug as OT-58, but its proper name is TVT-058, Pegtibatinase.
In November 2020, Retrophin acquired Orphan Technologies, thus also acquiring OT-58 and their Natural History Study. Shortly after, Retrophin rebranded as Travere.
Travere Therapeutics is in the process of developing an enzyme replacement therapy for patients with CBS Deficiency Homocystinuria.
For the most up-to-date news on their enzyme replacement, please visit their website: Click here
May 31, 2023
- Data from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline
- Pegtibatinase has been generally well-tolerated to date
- The Company is engaging with regulators and expects to initiate a pivotal Phase 3 Study by year-end 2023
January 09, 2023
Travere Therapeutics Provides Corporate Update and 2023 Outlook
October 27, 2022
Travere Therapeutics Reports Third Quarter 2022 Financial Results and
Corporate Updates
Travere Therapeutics, Inc. today reported its third quarter 2022 financial results and provided a corporate update.
A Breakthrough Therapy Designation was granted to the pegtibatinase development program for classical homocystinuria (HCU).
August 25, 2022
-
Population-based Incidence Estimates of Classical Homocystinuria Using the Genome Aggregation Database (gnomAD)
-
A Longitudinal Study of Cognitive Function in Classical Homocystinuria Demonstrates Distinct Deficits in Inhibitory Control
- Insights from the First Genetic Evaluation of a Longitudinal Natural History Study in Classical Homocystinuria (HCU)
August 3, 2022
Travere Therapeutics Provides Regulatory Updates on its Development Programs
-
Pegtibatinase granted Breakthrough Therapy Designation by FDA
